<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="tbl0005">
 <label>Table 1</label>
 <caption>
  <p>Summary of cited clinical trials.</p>
 </caption>
 <alt-text id="at0010">Table 1</alt-text>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="left">Study title</th>
    <th align="left">Status</th>
    <th align="left">Identification number</th>
    <th align="left">Location</th>
    <th align="left">Phase*</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left">Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation (CYCOV)</td>
    <td align="left">R</td>
    <td align="left">NCT04324528</td>
    <td align="left">Freiburg, Germany</td>
    <td align="left"/>
   </tr>
   <tr>
    <td align="left">Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation (CYCOV-II)</td>
    <td align="left">IP</td>
    <td align="left">NCT04385771</td>
    <td align="left">Freiburg, Germany</td>
    <td align="left"/>
   </tr>
   <tr>
    <td align="left">Early Haemadsorption in Major Burns</td>
    <td align="left">IP</td>
    <td align="left">NCT04195126</td>
    <td align="left">Pecs, Hungary</td>
    <td align="left"/>
   </tr>
   <tr>
    <td align="left">Adsorbtion of Cytokines Early in Septic Shock: the ACESS Study</td>
    <td align="left">C</td>
    <td align="left">NCT02288975</td>
    <td align="left">Szeged, Hungary</td>
    <td align="left"/>
   </tr>
   <tr>
    <td align="left">Cytokine Adsorption in Post-cardiac Arrest Syndrome in Patients Requiring Extracorporeal Cardiopulmonary Resuscitation (CYTER)</td>
    <td align="left">R</td>
    <td align="left">NCT03685383</td>
    <td align="left">Freiburg, Germany</td>
    <td align="left"/>
   </tr>
   <tr>
    <td align="left">Extracorporeal Cytokine Adsorption as Additive Treatment of CAR-T Associated Cytokine Release Syndrome (CRS) (CYTORELEASE)</td>
    <td align="left">IP</td>
    <td align="left">NCT04048434</td>
    <td align="left">Hannover, Germany</td>
    <td align="left"/>
   </tr>
   <tr>
    <td align="left">Effects of Endotoxin Absorption and Cytokine Removal Hemofilter on Severe Septic Shock</td>
    <td align="left">R</td>
    <td align="left">NCT03974386</td>
    <td align="left">Taipei, Taiwan</td>
    <td align="left"/>
   </tr>
   <tr>
    <td align="left">Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19 (COVID-19-HBO)</td>
    <td align="left">R</td>
    <td align="left">NCT04327505</td>
    <td align="left">Gelsenkirchen, Regensburg, Germany*** Blekinge, Sweden</td>
    <td align="left">Phase 2/3</td>
   </tr>
   <tr>
    <td align="left">Efficacy and Safety of Tocilizumab in the Treatment of SARS-Cov-2 Related Pneumonia (TOSCA)</td>
    <td align="left">R</td>
    <td align="left">NCT04332913</td>
    <td align="left">L'Aquila, Italy</td>
    <td align="left"/>
   </tr>
   <tr>
    <td align="left">Tocilizumab for Cytokine Release Syndrome Prophylaxis in Haploidentical Transplantation</td>
    <td align="left">R</td>
    <td align="left">NCT03533101</td>
    <td align="left">Monterrey, Mexico</td>
    <td align="left">**</td>
   </tr>
   <tr>
    <td align="left">Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome</td>
    <td align="left">IP</td>
    <td align="left">NCT02906371</td>
    <td align="left">Philadelphia (PA), US</td>
    <td align="left"/>
   </tr>
   <tr>
    <td align="left">Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID) (RUXCOVID)</td>
    <td align="left">R</td>
    <td align="left">NCT04362137</td>
    <td align="left">Multicentric (62 centers) worldwide</td>
    <td align="left">Phase 3</td>
   </tr>
   <tr>
    <td align="left">Ruxolitinib for the Treatment of Acute Respiratory Distress Syndrome in Patients With COVID-19 Infection (RESPIRE)</td>
    <td align="left">IP</td>
    <td align="left">NCT04361903</td>
    <td align="left">Pisa, Italy</td>
    <td align="left"/>
   </tr>
   <tr>
    <td align="left">Treatment of SARS Caused by COVID-19 With Ruxolitinib</td>
    <td align="left">R</td>
    <td align="left">NCT04334044</td>
    <td align="left">Huixquilucan, Mexico</td>
    <td align="left">Phase 1/2</td>
   </tr>
   <tr>
    <td align="left">Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study. (BARI-COVID)</td>
    <td align="left">IP</td>
    <td align="left">NCT04320277</td>
    <td align="left">Prato, Italy</td>
    <td align="left">Phase 2/3</td>
   </tr>
   <tr>
    <td align="left">Baricitinib Therapy in COVID-19</td>
    <td align="left">C</td>
    <td align="left">NCT04358614</td>
    <td align="left">Prato, Italy</td>
    <td align="left">Phase 2/3</td>
   </tr>
   <tr>
    <td align="left">Effects of Free Fatty Acids and 3-hydroxybutyrate on Protein, Glucose, Lipid Metabolism and Intracellular Signals</td>
    <td align="left">C</td>
    <td align="left">NCT01752348</td>
    <td align="left">Aarhus C, Denmark</td>
    <td align="left"/>
   </tr>
   <tr>
    <td align="left">Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome (COVIDIOL)</td>
    <td align="left">IP</td>
    <td align="left">NCT04366908</td>
    <td align="left">Córdoba, Spain</td>
    <td align="left">Phase 2</td>
   </tr>
   <tr>
    <td align="left">The Effect of D3 on Selected Cytokines Involved in Cytokine Storm in the Covid-19 Uninfected Jordanian People</td>
    <td align="left">IP</td>
    <td align="left">NCT04476745</td>
    <td align="left">Amman, Jordan</td>
    <td align="left"/>
   </tr>
   <tr>
    <td align="left">A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients (PRANA)</td>
    <td align="left">R</td>
    <td align="left">NCT04458298</td>
    <td align="left">Multicentric (5 centers), US</td>
    <td align="left">Phase 2</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>(* – if applicable, ** – active, but recruitment interrupted in 2018, *** – only Swedish center started to recruit, IP – in preparation, R – recruited, C – completed).</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
